A tethered ligand assay to probe SARS-CoV-2:ACE2 interactions.
Results
| Observable | Value | Source sentence |
|---|---|---|
| Unbinding force | 26 pN | an initial (leftmost) peak typically at lower forces around 26 pN for the SARS-CoV-1 fusion construct and about twice as high forces for the SARS-CoV-2 fusion construct (around 57 pN; Fig. 2 A, Inset) |
| Unbinding force | 57 pN | an initial (leftmost) peak typically at lower forces around 26 pN for the SARS-CoV-1 fusion construct and about twice as high forces for the SARS-CoV-2 fusion construct (around 57 pN; Fig. 2 A, Inset) |
| Unfolding force | 40 pN | This initial peak is followed by a trident-shaped, three-peak pattern at around 40 pN. |
| Contour length increment | 53 nm | The contour length increments of the first peaks (53 and 66 nm for the short and long linkers, respectively), are, however, larger than what is expected from interface opening only |
| Contour length increment | 66 nm | The contour length increments of the first peaks (53 and 66 nm for the short and long linkers, respectively), are, however, larger than what is expected from interface opening only |
| Rupture force | 1,500 pN | The final ClfA:Fgɣ rupture at >1,500 pN is not shown, for clarity. |
Auto-extracted; verify against the paper before reuse.
Biological system
- SARS-CoV-2 RBD:ACE2 tethered ligand fusion construct · protein
- SARS-CoV-1 RBD:ACE2 tethered ligand fusion construct · protein
- Human ACE2 (GLN18-SER740, C-terminal His-tag), soluble blocking agent · protein
- ClfA:fibrinogen gamma peptide anchoring pair · protein
Data availability
Abstract
SignificanceIn the dynamic environment of the airways, where SARS-CoV-2 infections are initiated by binding to human host receptor ACE2, mechanical stability of the viral attachment is a crucial fitness advantage. Using single-molecule force spectroscopy techniques, we mimic the effect of coughing and sneezing, thereby testing the force stability of SARS-CoV-2 RBD:ACE2 interaction under physiological conditions. Our results reveal a higher force stability of SARS-CoV-2 binding to ACE2 compared to SARS-CoV-1, causing a possible fitness advantage. Our assay is sensitive to blocking agents preventing RBD:ACE2 bond formation. It will thus provide a powerful approach to investigate the modes of action of neutralizing antibodies and other agents designed to block RBD binding to ACE2 that are currently developed as potential COVID-19 therapeutics.